|By PR Newswire||
|February 14, 2014 09:30 AM EST||
NEW YORK, Feb. 14, 2014 /PRNewswire/ -- The well-known science philanthropist and founder of the Program for Evolutionary Dynamics at Harvard University, has heralded the Food and Drug Administration's approval of the first inhibitor combination clinical trial for melanoma patients.
"It's about time," Jeffrey Epstein remarked who donated substantial funds to the Melanoma Research Alliance (MRA) over the last few years. Based in Washington DC, the MRA is the largest private funder of melanoma research and has awarded more than $49 million to researchers around the world.
A key area of research that the MRA funds is the use of inhibitor drugs to block melanoma cancer cells. Inhibitors are molecules that bind uniquely to a cancer cell's surface and block an aspect of that cell's functionality. For example, PARP inhibitors bind to an enzyme pathway found distinctly on breast cancer cells with a BRAC genetic mutation. The PARP molecule's attachment prevents the cell from performing DNA repair, leading to its death.
What researchers are realizing however is that a simultaneous cocktail of inhibitors is the most likely way to tackle the real problem of resistance. Indeed, the Program for Evolutionary Dynamics, along with Johns Hopkins University, has mathematically shown how cell resistance to a drug can quickly evolve from a tiny mutational pool to tumor level.
The inhibitor cocktail that was approved by the FDA is Dabrafenib and trametinib, which block certain BRAF enzyme pathway genetic mutations. These mutations occur in approximately 50% of melanoma patients and can be identified with a diagnostic test.
"Side effects need to be monitored. But many more combination drugs need to pass through the FDA's Accelerated Program," Jeffrey Epstein remarked, who heads the Jeffrey Epstein VI Foundation, which funds science research around the world. Indeed, the FDA only started to approve cancer inhibitors as a combined pill a few years ago. Prior to that, inhibitors had to be approved separately.
The situation is still dire. According to the National Cancer Institute, only 16% survive fully metastasized melanoma.
Jeffrey Epstein is a former board member of the Mind, Brain and Behavior Committee at Harvard.
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of at least three separate application components: the software embedded in the device, the backend big-data service, and the mobile application for the end user's controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/...
Oct. 7, 2015 12:45 AM EDT
Oct. 7, 2015 12:00 AM EDT Reads: 235
Oct. 7, 2015 12:00 AM EDT Reads: 502
Oct. 6, 2015 11:15 PM EDT Reads: 355
Oct. 6, 2015 10:00 PM EDT Reads: 651
Oct. 6, 2015 08:00 PM EDT Reads: 311
Oct. 6, 2015 05:00 PM EDT Reads: 254
Oct. 6, 2015 04:40 PM EDT Reads: 105
Oct. 6, 2015 03:00 PM EDT Reads: 122
Oct. 6, 2015 02:45 PM EDT Reads: 370
Oct. 6, 2015 02:00 PM EDT Reads: 228
Oct. 6, 2015 01:00 PM EDT Reads: 740
Oct. 6, 2015 01:00 PM EDT Reads: 580
Oct. 6, 2015 12:45 PM EDT Reads: 458
Clearly the way forward is to move to cloud be it bare metal, VMs or containers. One aspect of the current public clouds that is slowing this cloud migration is cloud lock-in. Every cloud vendor is trying to make it very difficult to move out once a customer has chosen their cloud. In his session at 17th Cloud Expo, Naveen Nimmu, CEO of Clouber, Inc., will advocate that making the inter-cloud migration as simple as changing airlines would help the entire industry to quickly adopt the cloud wit...
Oct. 6, 2015 12:30 PM EDT Reads: 585